Risk Factors Update Summary
- Added two new product candidates, BMF-500 and COVALENT-102, in clinical trials.
- Accumulated deficit increased from $131 million to $248 million as of December 31, 2023.
- Net losses increased from $81.8 million in 2022 to $117.3 million in 2023.
- Increased full-time employees from 83 to 103, including 78 engaged in research and development activities.
- Sold 5,750,000 shares of common stock at $30.00 per share for gross proceeds of $172.5 million.
- Independent registered public accounting firm ownership threshold increased from 27% to 29%.
- Added information on the competitive landscape and potential competition in the pharmaceutical industry.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1840439&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.